In Q2 2026, Eli Lilly reported a strong 48% revenue growth driven by blockbuster obesity drugs Mounjaro and Zepbound, especially with rapid international expansion. Novo Nordisk faced challenges including shrinking U.S. sales, price cuts, layoffs, and impairments, despite growth in Wegovy pill prescriptions. Lilly is advancing with promising new drugs and raised full-year guidance, while Novo focuses on stabilizing its business amid price pressures and restructuring. The next year will be critical for both, hinging on drug approvals, pricing strategies, and Medicare programs.
Vanguard Growth Index Fund Admiral Shares (VIGAX) is heavily concentrated, with about 44.6% of its assets in just four mega-cap tech stocks: NVIDIA, Apple, Alphabet, and Microsoft. This concentration means investors are effectively making a large bet...
Eli Lilly projects fiscal 2026 revenue between $85 billion and $87 billion, nearing the $100 billion mark. The company's stock is up nearly 78% over the past year, driven by strong Q2 2026 results including $22.97 billion revenue and significant sale...
The FDA has approved a new blood test developed by Roche and Eli Lilly to help identify Alzheimer's disease symptoms in patients over 55. The Elecsys Phospho-Tau (217P) Plasma test detects amyloid pathology, a brain marker linked to Alzheimer's, usin...
Eli Lilly has introduced Foundayo, an oral GLP-1 pill for weight loss and type 2 diabetes, in UK pharmacies following recent approval. This tablet offers a convenient alternative to injections and is licensed for adults with certain BMI criteria or w...
Eli Lilly reported a 47.67% revenue increase to $22.974 billion, driven by strong sales of Mounjaro at nearly $10 billion. Despite price pressures and higher tax rates, the company raised its full-year guidance, reflecting confidence in growth. Analy...
